Comparison of prandial air inhaled insulin alone to intensified insulin glargine alone and to air insulin plus intensified insulin glargine in patients with type 2 diabetes previously treated with once-daily insulin glargine

Diabetes Technology and Therapeutics

Volumn 11, Issue SUPPL. 2, 2009, Pages

  Rosenstock, Julio ^a   Eliaschewitz, Freddy G ^b   Heilmann, Cory R ^c   Muchmore, Douglas B ^d   Hayes, Risa P ^c   Belin, Ruth M ^c  

^a DALLAS DIABETES AND ENDOCRINE CENTER AT MEDICAL CITY   (United States)

^b HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^c ELI LILLY AND COMPANY   (United States)

^d Halozyme   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AIR INHALED INSULIN; HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE; INSULIN LISPRO; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SORE THROAT;

ADMINISTRATION, INHALATION; ADULT; AGED; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; LEAST-SQUARES ANALYSIS; MALE; MIDDLE AGED;

EID: 70349462772     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2009.0059     Document Type: Article

References (31)

1. Riddle MC, Rosenstock J, Gerich J: The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-3086.
2. Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G: Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care 2006;29:554-559.
3. Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G: A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulinnaive people with type 2 diabetes. Diabetologia 2008;51: 408-416.
4. Bastyr EJ3, StuartCA, BrodowsRG, Schwartz S,GrafCJ, Zagar A, Robertson KE: Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. IOEZ Study Group. Diabetes Care 2000;23:1236-1241.
5. Malone JK, Holcombe JH, Campaigne BN, Kerr LF: Insulin lispro mix75=25 compared to insulin glargine in patients with type 2 diabetes new to insulin therapy [abstract 576-P]. Diabetes 2004;53:A137.
6. Malone JK, Bai S, Campaigne BN, Reviriego J, Augendre- Ferrante B: Targeting postprandial rather than fasting blood glucose results in better overall glycemic control in patients with type 2 diabetes [abstract 577-P]. Diabetes 2004;53:A137.
7. Raskin P, Allen E, Hollander P, Lewin A, Gabbay RA, Hu P, Bode B, Garber A, INITIATE Study Group: Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005;28:260-265.
8. Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, Paul S, Levy JC: Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007;357:1716-1730.
9. Bretzel RG, Nuber U, Landgraf W, Owens DR, Bradley C, Linn T: Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet 2008;371:1073-1084.
10. Rave K, Bott S, Heinemann L, Sha S, Becker RH, Willavize SA, Heise T: Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. Diabetes Care 2005;28:1077-1082.
11. The Criteria Committee of the New York Heart Association: Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels, 9th ed. Boston, MA: Little, Brown & Co., 1994:253-256.
12. Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R: Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care 2005;28:1282-1288.
13. Rosenstock J, Muchmore D, Swanson D, Schmitke J: AIR Inhaled Insulin System: a novel insulin-delivery system for patients with diabetes. Expert Rev Med Devices 2007;4:683-692.
14. Bradley C: The 12-Item Well-Being Questionnaire: origins, current stage of development, and availability. Diabetes Care 2000;23:875.
15. Grootenhuis PA, Snoek FJ, Heine RJ, Bouter LM: Development of a type 2 diabetes symptom checklist: a measure of symptom severity. Diabet Med 1994;11:253-261.
16. Bradley C: The Diabetes Treatment Satisfaction Questionnaire (DTSQ). In: Bradley C, ed. Handbook of Psychology and Diabetes: A Guide to Psychological Measurement in Diabetes Research and Practice. Chur, Switzerland. Harwood Academic Publishers, 1994:111-132.
17. Marshall T, Silva S, Hayes C: Validation of the Insulin Delivery System Questionnaire (IDSQ) in patients with type 2 diabetes [abstract]. J Diabetes Sci Technol 2007;1(2):A109.
18. Garg SK, Mathieu C, Rais N, Gao H, Tobian JA, Gates JR, Ferguson JA, Webb DM, Berclaz P-Y: Two-year efficacy and safety of AIR inhaled insulin in patients with type 1 diabetes: an open-label randomized controlled trial. Diabetes Technol Ther 2009;11(Suppl 2):S-5-S-16.
19. Standardization of spirometry, 1994 update. American Thoracic Society. Am J Respir Crit Care Med 1995;152:1107-1136.
20. American Thoracic Society: Single-breath carbon monoxide diffusing capacity (transfer factor). Recommendations for a standard technique-1995 update. Am J Respir Crit Care Med 1995;152:2185-2198.
21. Comulada AL, Renard E, Nakano M, Rais N, Mao X, Webb DM, Milicevic Z: Efficacy and safety of AIR inhaled insulin compared to insulin lispro in patients with type 1 diabetes mellitus in a 6-month, randomized, noninferiority trial. Diabetes Technol Ther 2009;11(Suppl 2):S-17-S-25.
22. Akritas MG, Arnold SF, Brunner E: Nonparametric hypotheses and rank statistics for unbalanced factorial designs. J Am Stat Assoc 1997;92:258-265.
23. Rave KM, Nosek L, de la Peña A, Seger M, Ernest CS 2nd, Heinemann L, Batycky RP, Muchmore DB: Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro. Diabetes Care 2005;28:2400-2405.
24. Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M, Vahatalo M, Virtamo H, Nikkila K, Tulokas T, Hulme S, Hardy K, McNulty S, Hanninen J, Levanen H, Lahdenpera S, Lehtonen R, Ryysy L: Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 2006;49:442-451.
25. Yki-Jarvinen H, Juurinen L, Alvarsson M, Bystedt T, Caldwell I, Davies M, Lahdenpera S, Nijpels G, Vahatalo M: Initiate Insulin by Aggressive Titration and Education (INITIATE): a randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups. Diabetes Care 2007;30:1364-1369.
26. Rave K, Nosek L, Heinemann L, Gonzales C, Ernest CS, Chien J, Muchmore D: Inhaled micronized crystalline human insulin using a dry powder inhaler: dose-response and time-action profiles. Diabet Med 2004;21:763-768.
27. Quattrin T, Belanger A, Bohannon NJ, Schwartz SL; Exubera Phase III Study Group: Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 2004;27:2622-2627.
28. Skyler JS, Cefalu WT, Kourides IA, Landschulz WH, Balagtas CC, Cheng SL, Gelfand RA: Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study. Lancet 2001;357:331-335.
29. Skyler JS, Weinstock RS, Raskin P, Yale JF, Barrett E, Gerich JE, Gerstein HC; Inhaled Insulin Phase III Type 1 Diabetes Study Group: Use of inhaled insulin in a basal=bolus insulin regimen in type 1 diabetic subjects: a 6-month, randomized, comparative trial. Diabetes Care 2005;28:1630-1635.
30. Cefalu WT, Skyler JS, Kourides IA, Landschulz WH, Balagtas CC, Cheng S, Gelfand RA: Inhaled human insulin treatment in patients with type 2 diabetes mellitus. Ann Intern Med 2001;134:203-207.
31. Hollander PA, Blonde L, Rowe R, Mehta AE, Milburn JL, Hershon KS, Chiasson JL, Levin SR: Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6- month, randomized, comparative trial. Diabetes Care 2004; 27:2356-2362